Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Sturge-Weber syndrome (SWS) is described in the packet's definition as a rare congenital neurocutaneous disorder characterized by facial capillary malformations and, or, cerebral and ocular ipsilateral vascular malformations that result in variable degrees of ocular and neurological anomalies. The packet lists synonyms that include encephalotrigeminal angiomatosis and Sturge-Weber-Dimitri syndrome, along with three descriptive types: facial and leptomeningeal angiomas, facial angioma alone without central nervous system involvement, and isolated leptomeningeal angiomas.
Orphanet notation in the packet places the prevalence category as uncommon, at 1 to 9 per 100,000. The packet's curated data gives a birth prevalence of 1 in 20,000 to 50,000 births. The packet lists the inheritance pattern as sporadic and lists the affected organ systems as the eye and respiratory system.
The packet lists 52 associated phenotypes. Those reported in 80 to 99 percent of affected individuals are facial capillary hemangioma and capillary hemangioma. Phenotypes listed as frequent (30 to 79 percent) include abnormal cerebral vascular morphology, infantile spasms, neurodevelopmental delay, delayed speech and language development, stroke, headache, hyperreflexia, atypical behavior and attention deficit hyperactivity disorder. Eye-related findings in the same frequency band include glaucoma, strabismus, optic atrophy, visual field defect and lens luxation. Occasional phenotypes (5 to 29 percent) include dysphagia, pulmonary embolism, Chiari malformation and sleep disturbance.
The packet's curated characteristic findings are a port-wine stain (facial capillary malformation) in the V1 trigeminal distribution, a leptomeningeal angioma on brain imaging, seizures that are often refractory to medication, and glaucoma on the affected side. The packet does not certify an age-of-onset category.
According to the packet's molecular mechanism field, Sturge-Weber syndrome is caused by a somatic mosaic activating variant in the GNAQ gene. The same field states that this variant is not inherited from parents, arose during early embryonic development, and affects only a portion of the body's cells. The packet lists GNAQ, on chromosome 9, as the known gene; a ClinGen validity classification is not supplied in the packet. The packet lists the inheritance pattern as sporadic, and its curated findings state that the condition is not inherited and does not run in families.
The packet's curated diagnostic methods describe clinical diagnosis based on the characteristic port-wine stain and neurologic features. They also list brain MRI with contrast to detect a leptomeningeal angioma, ophthalmologic examination for glaucoma, and skin biopsy with GNAQ testing, which is described as able to confirm the diagnosis. The packet contains no newborn screening information for this condition.
The packet lists no FDA-approved treatment records for Sturge-Weber syndrome, so approved options are not certified here. Its orphan drug entries are two plasma-derived fibronectin products listed for non-healing corneal ulcers or epithelial defects, one withdrawn and one at designation stage; neither is a current approved option for this condition, and designation does not indicate approval or development.
The packet's curated foundational therapies list antiepileptic medications for seizure management, aspirin therapy described as reducing stroke-like episodes, pulsed-dye laser treatment for the port-wine stain, ophthalmologic monitoring with glaucoma treatment, and physical and occupational therapy for hemiparesis. The curated specialist types listed are neurologist, ophthalmologist, dermatologist, geneticist and physical therapist. No surveillance schedule is supplied in the packet.
Investigational directions named in the packet's curated data include MEK inhibitor therapies, novel anti-angiogenic approaches and improved laser treatments.
4 trials found
Prognosis is not certified in this packet. The packet's curated findings note that seizures are often refractory to medication, and its phenotype list includes stroke as a frequent feature, but no natural history information is supplied.
The packet certifies multiple active clinical studies for Sturge-Weber syndrome, all academic. They include longitudinal neuroimaging in Sturge-Weber syndrome, a study of approaches to gauge progression of the condition, and a study of neurocutaneous syndromes in children that has not yet begun recruiting. The packet's research literature digest describes the publication landscape as dominated by case reports and case series, with some publications on gene therapy and biomarkers. Active clinical trials for this condition are listed on ClinicalTrials.gov.
Data assembled from 7 of 12 sources · Last updated Nov 17, 2026, 7:06 PM UTC
Patient Advocacy Groups (PAGs) provide support, resources, and community for patients and caregivers.
Online Mendelian Inheritance in Man
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Sturge-Weber syndrome
AI-curated news mentioning Sturge-Weber syndrome
Updated Aug 26, 2026
A new study introduces the Feed-and-Swaddle FAST Protocol for imaging Sturge-Weber Syndrome, enhancing diagnostic capabilities. This innovative approach aims to improve patient comfort and imaging quality.